Home
  • E-mailGeir.Skeie@uib.no
  • Phone+47 55 97 50 75
  • Visitor Address
    Lars Hillesgt. 3
  • Postal Address
    Postboks 7800
    5020 Bergen
Academic article
  • 2019. Subjective judgments of rhythmic complexity in Parkinson's disease: Higher baseline, preserved relative ability, and modulated by tempo. PLOS ONE. 1-21.
  • 2019. Neuroplastic effects in patients with traumatic brain injury after music-supported therapy. Frontiers in Human Neuroscience. 1-11.
  • 2019. Compensatory task-specific hypersensitivity in bilateral planum temporale and right superior temporal gyrus during auditory rhythm and omission processing in Parkinson?s disease. Scientific Reports. 1-9.
  • 2019. A prospective study of the natural history of incidental meningioma-Hold your horses! Neuro-Oncology Practice. 438-450.
  • 2018. Predictors of quality of life and survival following Gamma Knife surgery for lung cancer brain metastases: a prospective study. Journal of Neurosurgery. 71-83.
  • 2018. Myasthenia gravis and infectious disease. Journal of Neurology. 1251-1258.
  • 2018. Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson's disease. Acta Neurologica Scandinavica. 508-514.
  • 2018. HLA and MuSK-positive myasthenia gravis: A systemic review and meta-analysis. Acta Neurologica Scandinavica. 219-226.
  • 2018. Effects of music production on cortical plasticity within cognitive rehabilitation of patients with mild traumatic brain injury. Brain Injury. 634-643.
  • 2018. Abnormal phasic activity in saliency network, motor areas, and basal ganglia in Parkinson's disease during rhythm perception. Human Brain Mapping. 916-927.
  • 2017. Neuronal complex I deficiency occurs throughout the Parkinson's disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage. Acta Neuropathologica. 409-425.
  • 2017. Multiple antibody detection in `seronegative? myasthenia gravis patients. European Journal of Neurology. 844-850.
  • 2017. Juvenile-onset myasthenia gravis: autoantibody status, clinical characteristics and genetic polymorphisms. Journal of Neurology. 955-962.
  • 2017. Familial aggregation of Parkinson's disease may affect progression of motor symptoms and dementia. Movement Disorders. 241-245.
  • 2016. Myasthenia gravis and amyotrophic lateral sclerosis: A pathogenic overlap. Neuromuscular Disorders. 337-341.
  • 2016. Gene polymorphisms for both auto-antigen and immune-modulating proteins are associated with the susceptibility of autoimmune myasthenia gravis. Molecular Neurobiology. 10 pages.
  • 2016. Autoantibody profile and clinical characteristics in a cohort of Chinese adult myasthenia gravis patients. Journal of Neuroimmunology. 51-57.
  • 2015. En kvinne med kraftsvikt i armer og bein. Tidsskrift for Den norske legeforening.
  • 2014. The factor structure of the UPDRS motor scores changes during early Parkinson's disease. Parkinsonism & Related Disorders. 617-621.
  • 2013. Treatment in early Parkinson's disease: the Norwegian ParkWest study. Acta Neurologica Scandinavica. 107-113.
  • 2013. Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study. Parkinsonism & Related Disorders. 53-55.
  • 2013. Gamma knife surgery of colorectal brain metastases: a high prescription dose of 25 Gy may improve growth control. World Neurosurgery. 525-536.
  • 2013. Autonomic symptoms and dopaminergic treatment in de novo Parkinson's disease. Acta Neurologica Scandinavica. 290-294.
  • 2012. The Effect of Group Music Therapy on Mood, Speech, and Singing in Individuals with Parkinson's Disease - A Feasibility Study. The Journal of music therapy. 278-302.
  • 2012. Focal myositis - A neurogenic phenomenon? Neuromuscular Disorders. 350-354.
  • 2012. Effects of music therapy on facial expression of individuals with Parkinson's disease: A pilot study. Musicae Scientiae. 392-400.
  • 2011. Myasthenia gravis; a review of available treatment approaches. Autoimmune Diseases. 8 pages.
  • 2011. Myasthenia gravis autoantibodies have a target also outside the neuromuscular junction. Advances in Clinical Neuroscience & Rehabilitation. 14-15.
  • 2011. Investigation for RAPSN and DOK-7 mutations in a cohort of seronegative myasthenia gravis patients. Muscle and Nerve. 574-577.
  • 2011. Gamma Knife Surgery of Colorectal Brain Metastases: A High Prescription Dose of 25 Gy May Improve Growth Control. World Neurosurgery. 684-691.
  • 2011. Gamma Knife Surgery in Brain Melanomas: Absence of Extracranial Metastases and Tumor Volume Strongest Indicators of Prolonged Survival. World Neurosurgery. 684-691.
  • 2011. Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s Disease : frequent but mild. Movement Disorders. 65-72.
  • 2010. Guidelines for treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology. 893-902.
  • 2010. Gamma knife surgery of meningiomas involving the cavernous sinus: long-term follow-up of 100 patients. Neurosurgery. 661-669.
  • 2010. Differential Effect of Environmental Risk Factors on Postural Instability Gait Difficulties and Tremor Dominant Parkinson's Disease. Movement Disorders. 1847-1852.
  • 2009. Myasthenia gravis in the elderly. Aging Health. 561-568.
  • 2009. Interleukin-10 promoter polymorphisms in myasthenia gravis. Journal of Neuroimmunology. 63-66.
  • 2009. Aphasia among Young Patients with Ischemic Stroke on Long-term Follow-up. Journal of Stroke & Cerebrovascular Diseases. 247-250.
  • 2008. Titin and ryanodine receptor antibodies and neurmuscular involvement in myasthenia gravis. Future Neurology. 87-92.
  • 2008. CRMP5 antibodies in patients with small-cell lung cancer or thymoma. Cancer Immunology and Immunotherapy. 227-232.
  • 2007. Polygenic disease associations in thymomatous myasthenia gravis. Archives of Neurology. 1729-1733.
  • 2006. Titin and ryanodine receptor antibodies in myasthenia gravis. Acta Neurologica Scandinavica. 19-23.
  • 2006. Morphological effects of myasthenia gravis patient sera on human muscle cells. Muscle and Nerve. 93-103.
  • 2006. Guidelines for the treatment of autoimmune neuromuscular transmission disorders. European Journal of Neurology. 691-699.
  • 2006. Effects of myasthenia gravis patient sera on human myoblast cultures. Acta Neurologica Scandinavica. 28-32.
  • 2004. Cytoxic Effects of Myasthenia Gravis Patient Sera on Primary Human Skeletal Muscle Cell Cultures. Immunology. 131-134.
  • 2003. Thymectomy and antimuscle antibodies in nonthymomatous myasthenia gravis. Annals of the New York Academy of Sciences. 481-490.
  • 2003. Ryanodine receptor antibodies in myasthenia gravis: epitope mapping and effect on calcium release in vitro. Muscle &Nerve. 81-89.
  • 2003. Pathogenesis of myositis and myasthenia associated with titin and ryanodine receptor antibodies. Annals of the New York Academy of Sciences. 350-353.
  • 2003. Myasthenia gravis in individuals over forty. Annals of the New York Academy of Sciences. 424-431.
  • 2002. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules. Journal of Neuroimmunology. 82-89.
  • 2002. Thymectomy and anti-muscle autoantibodies in late-onset myasthenia gravis. European Journal of Neurology. 55-61.
  • 2001. Autoimmunity against the ryanodine receptor in myasthenia gravis. Acta Physiologica Scandinavica. 379-384.
  • 2000. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Archives of Neurology. 1596-1600.
  • 2000. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Archives of Neurology. 1596-1600.
  • 2000. Skeletal muscle titin: physiology and pathophysiology. Cellular and Molecular Life Sciences (CMLS). 1570-1576.
  • 2000. Skeletal muscle titin: physiology and pathophysiology. Cellular and Molecular Life Sciences (CMLS). 1570-1576.
  • 2000. Muscle autoantibodies in subgroups of myasthenia gravis patients. Journal of Neurology. 369-375.
  • 2000. Muscle autoantibodies in subgroups of myasthenia gravis patients. Journal of Neurology. 369-375.
  • 2000. Complement activation by titin and ryanoidine receptor autoantibodies in myasthenia gravis. Journal of Neuroimmunology. 169-176.
  • 2000. Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. Journal of Neuroimmunology. 169-176.
  • 1999. TNFB polymorphisms in myasthenia gravis. Archives of Neurology. 457-461.
  • 1998. Titin transcripts in thymoma. Annals of the New York Academy of Sciences. 422-426.
  • 1998. The histomorphology of the thymus in late onset, non-thymoma myasthenia gravis. European Journal of Neurology. 401-405.
  • 1998. Striational autoantibodies in myasthenia gravis patients recognizw I-band titin epitopes. Journal of Neuroimmunology. 98-108.
  • 1998. Myasthenia gravis-associated ryanodine receptor antibodies inhibit binding of ryanodine to sarcoplasmic reticulum. Annals of the New York Academy of Sciences. 530-533.
  • 1998. Myasthenia gravis sera containing anti-ryanodine receptor antibodies inhibit binding of (3H-) ryanodine to sarcoplasmic reticulum. Muscle and Nerve. 329-335.
  • 1998. Muscle striation antibodies in myasthenia gravis; diagnostic and functional significance. Annals of the New York Academy of Sciences. 505-515.
  • 1998. FcgRIIA and RIIIB polymorphisms in myasthenia gravis. Journal of Neuroimmunology. 173-176.
  • 1998. Cell-mediated immune response against titin in myasthenia gravis; evidence for the involvment of Th1 and Th2 cells. Scandinavian Journal of Immunology. 76-82.
  • 1998. Ataksi på grunn av vitamin E-mangel. Tidsskrift for Den norske legeforening. 3126-3128.
  • 1997. Titin transcript in thymomas. Journal of Autoimmunity. 551-557.
  • 1997. Titin antibody positive myasthenia gravis patients have a cellular immune response against the main immunogenic region of titin. European Journal of Neurology. 131-137.
  • 1997. Diagnostikk av thymom og thymusatrofi hos pasienter med myasthenia gravis. Tidsskrift for Den norske legeforening. 4212-4214.
  • 1997. Autoimmunity to ryanodine receptor and titin in myasthenia gravis is associated with GM allotypes. Autoimmunity. 111-116.
Academic lecture
  • 2013. Musikk, terapi og nevrologiske sykdommer.
  • 2002. Titin and ryanodine receptor epitopes are expressed in cortical thymoma along with co-stimulatory molecules.
  • 2001. Thymectomy and muscle autoantibodies in myasthenia gravis.
Popular scientific article
  • 2015. Musikk som terapi for ALS. Slagordet : tidsskrift for Landsforeningen for slagrammede.
Doctoral dissertation
  • 2019. Complexity in Rhythm and Parkinson’s disease: Cognitive and Neuronal Correlates.
  • 1998. Autoimmunity against titin and ryanodine receptor in myasthenia gravis. Clinical and immunological aspects. -.
Interview
  • 2013. Lydverket 25.06.2013. Hva skjer når vi skrur opp volumet og hører på høy musikk?
Programme participation
  • 2010. Schrødingers Katt, NRK: Musikk - magisk medisin.
Academic chapter/article/Conference paper
  • 2011. Autoimmune neuromuscular transmission disorders. 12 pages.
  • 2006. Autoimmune neuromuscular conduction disorders. 12 pages.
  • 1997. Myasthenia gravis patients have a cellular immune response against titin. 8 pages.
  • 1997. Accessory molecule expression in human thymomas and thymus. 6 pages.
Abstract
  • 2009. Interleukin-10 promoter polymorphisms in myasthenia gravis. European Journal of Neurology. 49-49.
Poster
  • 2018. Hyposmia and cognitive decline in early Parkinson's disease.
Academic literature review
  • 2016. Myasthenia gravis - Autoantibody characteristics and their implications for therapy. 259-268.
  • 2011. Musikkterapi innen nevrorehabilitering - med vekt på hvordan plastisitet kan utnyttes :. 21-25.
  • 2006. Unusual features in a boy with the rapsyn N88K mutation. 2262-2263.

More information in national current research information system (CRIStin)